Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01CJY
|
|||
| Former ID |
DIB013311
|
|||
| Drug Name |
FR-146687
|
|||
| Synonyms |
FK-687; TF-505; 4-[1-[4-[1(S)-(4-Isobutylphenyl)butoxy]benzoyl]indolizin-3-yl]butyric acid
Click to Show/Hide
|
|||
| Indication | Prostate disease [ICD-11: GA91; ICD-10: N42.9] | Phase 2 | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Steroid 5-alpha-reductase 1 (SRD5A1) | Target Info | Inhibitor | [1] |
| BioCyc | Superpathway of steroid hormone biosynthesis | |||
| Allopregnanolone biosynthesis | ||||
| Androgen biosynthesis | ||||
| KEGG Pathway | Steroid hormone biosynthesis | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathwhiz Pathway | Androgen and Estrogen Metabolism | |||
| Reactome | Androgen biosynthesis | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. Br J Clin Pharmacol. 2002 Sep;54(3):283-94. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.